We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CAP:EURONEXT PARISCapgemini SE Analysis

Data as of 2026-05-29 - not real-time

$9.26

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rithm Capital Corp. (CAP) is trading at $9.26, well below its 20‑day ($9.46) and 50‑day ($9.59) simple moving averages, signaling a short‑term bearish bias. The stock sits above a firm support around $8.93 but remains under the near‑term resistance of $9.95, while the MACD histogram is negative and the RSI hovers near 40, suggesting limited upside momentum. Fundamentally, the company appears markedly cheap – a trailing P/E of 8.5 versus an industry average of 32.6 and a price‑to‑book of 0.74 – and it offers an eye‑catching dividend yield of 10.8% with a payout ratio near 92%. However, the balance sheet is heavily strained, with debt exceeding $40 billion, a debt‑to‑equity ratio over 400, and negative operating cash flow, raising doubts about the sustainability of that dividend.
The high 30‑day volatility (≈23%) and a max drawdown of over 30% underscore the stock’s risk profile, yet analyst consensus leans strongly bullish (median target $13.5) and the upside/downside projection exceeds 45%. If the firm can stabilize cash generation and manage its leverage, the valuation gap and robust revenue growth (≈65% YoY) could translate into substantial medium‑ to long‑term gains.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below 20‑day and 50‑day SMAs
  • Bearish MACD and neutral RSI
  • Elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Significant valuation discount to peers
  • Strong revenue growth and high dividend yield
  • Outstanding debt load and negative cash flow

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Low P/E and P/B relative to industry
  • Projected upside of ~47% versus current price
  • Potential for cash‑flow improvement and debt reduction

Key Metrics & Analysis

Financial Health

Revenue Growth64.60%
Profit Margin17.00%
P/E Ratio8.5
ROE8.46%
ROA1.51%
Debt/Equity422.94
P/B Ratio0.7
Op. Cash Flow$-2612631040
Industry P/E32.6

Technical Analysis

TrendBearish
RSI40.4
Support$8.93
Resistance$9.95
MA 20$9.46
MA 50$9.59
MA 200$10.81
MACDBearish
VolumeStable
Fear & Greed Index93.23

Valuation

Target Price$13.61
Upside/Downside46.99%
GradeUndervalued
TypeBlend
Dividend Yield10.80%

Risk Assessment

Beta0.82
Volatility23.01%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.